JP2022534973A - 自閉症スペクトラム障害を治療するための選択的ヒスタミンｈ３受容体アンタゴニスト - Google Patents

自閉症スペクトラム障害を治療するための選択的ヒスタミンｈ３受容体アンタゴニスト Download PDF

Info

Publication number
JP2022534973A
JP2022534973A JP2021570821A JP2021570821A JP2022534973A JP 2022534973 A JP2022534973 A JP 2022534973A JP 2021570821 A JP2021570821 A JP 2021570821A JP 2021570821 A JP2021570821 A JP 2021570821A JP 2022534973 A JP2022534973 A JP 2022534973A
Authority
JP
Japan
Prior art keywords
asd
treatment
compound
pharmaceutically acceptable
symptoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021570821A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022534973A5 (https=
Inventor
ロマーン、ヴィクトル
イシュトバーン リーバイ、ジョルジュ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Richter Gedeon Nyrt
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of JP2022534973A publication Critical patent/JP2022534973A/ja
Publication of JP2022534973A5 publication Critical patent/JP2022534973A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
    • A61J3/071—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use into the form of telescopically engaged two-piece capsules
    • A61J3/074—Filling capsules; Related operations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021570821A 2019-05-31 2020-05-29 自閉症スペクトラム障害を治療するための選択的ヒスタミンｈ３受容体アンタゴニスト Pending JP2022534973A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HUP1900190 2019-05-31
HUP1900190A HU231525B1 (hu) 2019-05-31 2019-05-31 Szelektív hisztamin H3 receptor antagonisták autizmus spektrum betegség kezelésére
PCT/IB2020/055104 WO2020240489A1 (en) 2019-05-31 2020-05-29 Selective histamine h3 receptor antagonists for treating autism spectrum disorder

Publications (2)

Publication Number Publication Date
JP2022534973A true JP2022534973A (ja) 2022-08-04
JP2022534973A5 JP2022534973A5 (https=) 2023-06-06

Family

ID=89992916

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021570821A Pending JP2022534973A (ja) 2019-05-31 2020-05-29 自閉症スペクトラム障害を治療するための選択的ヒスタミンｈ３受容体アンタゴニスト

Country Status (8)

Country Link
US (1) US20220235034A1 (https=)
EP (1) EP3976035A1 (https=)
JP (1) JP2022534973A (https=)
CN (1) CN113905736A (https=)
CA (1) CA3141694A1 (https=)
EA (1) EA202193155A1 (https=)
HU (1) HU231525B1 (https=)
WO (1) WO2020240489A1 (https=)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016510067A (ja) * 2013-03-06 2016-04-04 リヒター ゲデオン ニルバーノシャン ミーケデーレスベニュタールシャシャーグ フェノキシピペリジンコア構造を含むｈ３アンタゴニスト

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE354568T1 (de) * 2000-08-08 2007-03-15 Ortho Mcneil Pharm Inc Nicht-imidazol aryloxypiperidine als h3 rezeptor liganden

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016510067A (ja) * 2013-03-06 2016-04-04 リヒター ゲデオン ニルバーノシャン ミーケデーレスベニュタールシャシャーグ フェノキシピペリジンコア構造を含むｈ３アンタゴニスト

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PLOS ONE, vol. 10(1), JPN6024017235, 2015, pages 0116363, ISSN: 0005480299 *
SCI. REP., vol. 8:13077, JPN6024017236, 2018, ISSN: 0005480300 *

Also Published As

Publication number Publication date
HU231525B1 (hu) 2024-08-28
US20220235034A1 (en) 2022-07-28
EA202193155A1 (ru) 2022-03-22
CA3141694A1 (en) 2020-12-03
WO2020240489A1 (en) 2020-12-03
CN113905736A (zh) 2022-01-07
EP3976035A1 (en) 2022-04-06
HUP1900190A1 (hu) 2020-12-28

Similar Documents

Publication Publication Date Title
JP5460594B2 (ja) ドーパミン受容体リガンドを含有する医薬組成物およびドーパミン受容体リガンドを用いる処置方法
CA3079259A1 (en) Ganaxolone for use in treating genetic epileptic disorders
JP2025143406A (ja) 自閉症スペクトラム障害を治療するためのカルバモイルシクロヘキサン誘導体
CN107567444A (zh) 用于治疗精神分裂症的包含2‑((1‑(2‑(4‑氟苯基)‑2‑氧代乙基)哌啶‑4‑基)甲基)异吲哚啉‑1‑酮的组合物
JP2020075933A (ja) ストレス性疾患の予防および／または治療用医薬
US20230181572A1 (en) Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
WO2017197177A1 (en) Compounds to promote normal processing of app
US20140212486A1 (en) Isometheptene isomer
JP2022534973A (ja) 自閉症スペクトラム障害を治療するための選択的ヒスタミンｈ３受容体アンタゴニスト
EA046455B1 (ru) Селективные антагонисты h3-гистаминовых рецепторов для лечения расстройства аутистического спектра
Janssen et al. Influence of 5-HT1 receptor agonists on feline stomach relaxation
EA048505B1 (ru) Производные карбамоилциклогексана для лечения расстройства аутистического спектра
HK40067131B (en) Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
HK40067131A (en) Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
OA20885A (en) Carbamoyl cyclohexane derivatives for treating autism spectrum disorder.
TW201630604A (zh) 纖維肌痛症之預防及／或治療劑
HK1091403A1 (zh) 5-ht1a受体亚型兴奋剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230529

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230529

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240507

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240730

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241107

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241210